Retatrutide is an investigational peptide that acts as a triple agonist at GIP, GLP-1, and glucagon receptors, currently in clinical development for obesity and type 2 diabetes (Jastreboff et al
Eloralintide (LY3841136): A novel selective amylin receptor agonist designed to enhance satiety, slow gastric emptying, and reduce caloric intake through amylin pathway signaling
Stay informed and engaged in your health decisions, and always consider the full scope of potential outcomes when starting new treatments.
Be cautious with compounded medications Compounded GLP-1 formulations show 2.5 times higher hospitalization rates compared to FDA-approved products
Using a quasi-experimental design, this study showed sustained effectiveness and cost-effectiveness
Never reconstitute or self-dose without written instructions from your provider